The study is a single-center, open, single-dose, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects.Subjects will take the SHR6390 on Day1 and Day22 , and from Day8 to Day26 take the efavirenz.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
20
SHR6390 tablet single dose;Efavirenz single dose.
Xuanwu Hospital Beijing, Capital Medical University
Beijing, Beijing Municipality, China
Tmax
Time to maximum observed serum concentration (Tmax) for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
Cmax
Maximum observed serum concentration (Cmax)for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
AUC0-t
Area under the plasma concentration versus time curve (AUC0-t) for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
AUC0-inf
Area under the plasma concentration versus time curve (AUC0-inf ) for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
T1/2
Time to elimination half-life (T1/2) for for SHR6390 after Single dose.
Time frame: from Day 1 to Day 7 after the first dose and from Day 22 to Day 27 after the second dose
Number of subjects with adverse events and severity of adverse events
Time frame: from Day 1 to Day 34 after the first dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.